search
Back to results

Effects of Therapeutic Mobile Game on Anxiety

Primary Purpose

Social Anxiety Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ABM-01
Digital Control
Sponsored by
Hunter College of City University of New York
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Social Anxiety Disorder

Eligibility Criteria

22 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults 22-65 at the time of screening
  • Meets DSM-5 diagnostic criteria for Social Anxiety Disorder
  • Access to and willingness to use computer equipment/smartphone compatible with the product platform over a functional network for the study duration.
  • Currently residing in the United States

Exclusion Criteria:

  • Risk of suicide or has attempted suicide within 24 months of the screening visit
  • Moderate to severe substance use disorder
  • Current co-morbid psychiatric diagnosis including PTSD, Schizophrenia, Bipolar Disorder I or II, or Borderline Personality Disorder
  • Currently pregnant or planning to become pregnant during the treatment period

Sites / Locations

  • Hunter College of the City University of New York

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental group

Placebo Control

Arm Description

Participants receive active ABM-01 for the study

Participants receive a digital control for the study

Outcomes

Primary Outcome Measures

The Liebowitz Social Anxiety Scale (LSAS)
A 24-item, self-rated scale to assess social anxiety in situations as well as the level of avoidance of those situations. Each question is rated on a 4-point scale, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Greater scores indicate greater symptom severity.

Secondary Outcome Measures

The Liebowitz Social Anxiety Scale (LSAS)
A 24-item, self-rated scale to assess social anxiety in situations as well as the level of avoidance of those situations. Each question is rated on a 4-point scale, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Scores above 55 indicate social phobia.
Generalized Anxiety Disorder - 7 (GAD-7)
A 7-item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day. Scores range from 0-21, where greater scores indicate greater anxiety symptoms.
Beck Anxiety Inventory (BAI)
A 21-Item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = mildly but it didn't bother me much, 2 = moderately - it wasn't pleasant at times, and 3 = severely, it bothered me a lot. Higher scores indicate more severe anxiety symptoms.
State-Trait Anxiety Scale (STAI)
A 40-Item self-report measure to assess symptoms of state and trait anxiety. There are 20 questions for state anxiety and 20 questions assessing trait anxiety. Each question is rate on a 4-point scale, where 1 = not at all, 2 = somewhat, 3 = moderately so, and 4 = very much so. Greater scores indicate more severe anxiety symptoms.
Hamilton Anxiety Rating Scale (HAM-A)
A 14-Item self-report measure to assess symptoms of anxiety. Each item is scored on a scale of 0 = not present to 4 = severe, with a total score range of 0-56. Greater scores indicate more severe anxiety symptoms.
Depression, Anxiety, and Stress Scale (DASS-21)
A 21-Item anxiety, depression, and stress measure. Consisted of anxiety, depression, and stress sub-scales. Each question is rated on a 4-point scale, where 0 = did not apply to me at all, 1 = applied to me to some degree, or some of the time, 2 = applied to me to a considerable degree or a good part of time, and 3 = applied to me very much or most of the time. Greater scores indicate greater symptom severity. Anxiety subscale only.
Generalized Anxiety Disorder-7 (GAD-7)
A 7-item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day. Scores range from 0-21, where greater scores indicate greater anxiety symptoms.

Full Information

First Posted
January 24, 2022
Last Updated
October 3, 2023
Sponsor
Hunter College of City University of New York
Collaborators
Arcade Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05240794
Brief Title
Effects of Therapeutic Mobile Game on Anxiety
Official Title
Effects of Therapeutic Mobile Game on Anxiety
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
June 15, 2022 (Actual)
Primary Completion Date
May 31, 2023 (Actual)
Study Completion Date
May 31, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hunter College of City University of New York
Collaborators
Arcade Therapeutics Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Participants with Social Anxiety Disorder (SAD) will use a digital therapeutic for 30 days, and will complete assessments measuring a broad range of anxiety and mood-related symptoms, with a focus on SAD symptoms, and metrics of functional impairment during this time. After the treatment period, participants will be followed at 6 month and 12 month after the completion of the study.
Detailed Description
This study aims to assess the feasibility and efficacy of the digital therapeutic ABM-01 in adults ages 22-65 with SAD. Participants access ABM-01 on their mobile smart phone and complete treatment over a period of 30 days. Enrolled participants will be randomly assigned to one of two groups (Experimental Group and Placebo Control) and be assessed over five periods of time (Baseline Session, 30-Day Treatment Phase, Post-Treatment Session, 6-Month Follow Up Session, 12-Month Follow Up Session). Participants will complete the 30-Day Treatment Phase as well as the five assessments remotely. During the treatment period, participants complete assessments social anxiety and generalized anxiety symptoms, as well as safety and medication use questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Social Anxiety Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
Participants receive active ABM-01 for the study
Arm Title
Placebo Control
Arm Type
Placebo Comparator
Arm Description
Participants receive a digital control for the study
Intervention Type
Device
Intervention Name(s)
ABM-01
Intervention Description
Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
Intervention Type
Device
Intervention Name(s)
Digital Control
Intervention Description
Placebo control for ABM-01
Primary Outcome Measure Information:
Title
The Liebowitz Social Anxiety Scale (LSAS)
Description
A 24-item, self-rated scale to assess social anxiety in situations as well as the level of avoidance of those situations. Each question is rated on a 4-point scale, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Greater scores indicate greater symptom severity.
Time Frame
Baseline to Treatment End (30 days)
Secondary Outcome Measure Information:
Title
The Liebowitz Social Anxiety Scale (LSAS)
Description
A 24-item, self-rated scale to assess social anxiety in situations as well as the level of avoidance of those situations. Each question is rated on a 4-point scale, where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Scores above 55 indicate social phobia.
Time Frame
Bi-weekly time point and at the 6 and 12 month follow-ups
Title
Generalized Anxiety Disorder - 7 (GAD-7)
Description
A 7-item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day. Scores range from 0-21, where greater scores indicate greater anxiety symptoms.
Time Frame
Bi-weekly time point and at the 6 and 12 month follow-ups
Title
Beck Anxiety Inventory (BAI)
Description
A 21-Item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = mildly but it didn't bother me much, 2 = moderately - it wasn't pleasant at times, and 3 = severely, it bothered me a lot. Higher scores indicate more severe anxiety symptoms.
Time Frame
Baseline to Treatment End (30 days)
Title
State-Trait Anxiety Scale (STAI)
Description
A 40-Item self-report measure to assess symptoms of state and trait anxiety. There are 20 questions for state anxiety and 20 questions assessing trait anxiety. Each question is rate on a 4-point scale, where 1 = not at all, 2 = somewhat, 3 = moderately so, and 4 = very much so. Greater scores indicate more severe anxiety symptoms.
Time Frame
Baseline to Treatment End (30 days)
Title
Hamilton Anxiety Rating Scale (HAM-A)
Description
A 14-Item self-report measure to assess symptoms of anxiety. Each item is scored on a scale of 0 = not present to 4 = severe, with a total score range of 0-56. Greater scores indicate more severe anxiety symptoms.
Time Frame
Baseline to Treatment End (30 days)
Title
Depression, Anxiety, and Stress Scale (DASS-21)
Description
A 21-Item anxiety, depression, and stress measure. Consisted of anxiety, depression, and stress sub-scales. Each question is rated on a 4-point scale, where 0 = did not apply to me at all, 1 = applied to me to some degree, or some of the time, 2 = applied to me to a considerable degree or a good part of time, and 3 = applied to me very much or most of the time. Greater scores indicate greater symptom severity. Anxiety subscale only.
Time Frame
Baseline to Treatment End (30 days)
Title
Generalized Anxiety Disorder-7 (GAD-7)
Description
A 7-item self-report measure to assess symptoms of anxiety. Each question is rated on a 4-point scale, 0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day. Scores range from 0-21, where greater scores indicate greater anxiety symptoms.
Time Frame
Baseline to Treatment End (30 days)
Other Pre-specified Outcome Measures:
Title
Anxiety Sensitivity Index (ASI-3)
Description
A 18-Item self-report measure to assess symptoms of anxiety. Each question is rated on a 5-point scale, where 0 = very little, 1 = a little, 2 = some, 3 = much, and 4 = very much. Greater scores on the scale indicate more severe anxiety symptoms.
Time Frame
Baseline to Treatment End (30 days)
Title
Positive and Negative Affect Schedule (PANAS)
Description
A 20-Item self-reported assessment of positive (10 items) and negative affect (10 items). Each question is rated on a 5-point scale, where 1 = very slightly or not at all, 2 = a little, 3 = moderately, 4 = quite a bit, and 5 = extremely. Greater scores indicate greater positive or negative affect.
Time Frame
Baseline to Treatment End (30 days)
Title
Beck Depression Inventory II (BDI-II)
Description
A 21-Item self-report measure to assess symptoms of depression. Each question is rated on a 4-point scale, where greater scores indicate greater depressive symptoms.
Time Frame
Baseline to Treatment End (30 days)
Title
Patient Health Questionnaire (PHQ-2)
Description
A 2-Item health questionnaire that measures the frequency of depressed mood and anhedonia. Each question is rated on a 4-point scale, where 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. Greater scores indicate more severe symptom severity.
Time Frame
Baseline to Treatment End (30 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults 22-65 at the time of screening Meets DSM-5 diagnostic criteria for Social Anxiety Disorder Access to and willingness to use computer equipment/smartphone compatible with the product platform over a functional network for the study duration. Currently residing in the United States Exclusion Criteria: Risk of suicide or has attempted suicide within 24 months of the screening visit Moderate to severe substance use disorder Current co-morbid psychiatric diagnosis including PTSD, Schizophrenia, Bipolar Disorder I or II, Autism Spectrum Disorder, or Borderline Personality Disorder Currently pregnant or planning to become pregnant during the treatment period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tracy A Dennis-Tiwary, PhD
Organizational Affiliation
City University of New York, School of Public Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hunter College of the City University of New York
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effects of Therapeutic Mobile Game on Anxiety

We'll reach out to this number within 24 hrs